OrthoCentric Liner, Cross-Linked Polyethylene - Non-constrained polyethylene acetabular liner Australia - English - Department of Health (Therapeutic Goods Administration)

orthocentric liner, cross-linked polyethylene - non-constrained polyethylene acetabular liner

orthocentric pty ltd - 43168 - non-constrained polyethylene acetabular liner - the orthocentric cross linked polyethylene liner is fitted into the acetabular shell. the inner surface of the liner is shaped to fit the new femoral head. the liner is available in a range of sizes with 0 degree neutral or 20 degree hooded configuration. upon implantation, the assembly of these components is designed to replace the natural articulation of the hip joint. the orthocentric cross linked polyethylene liner is a component of an acetabular system (cup) made of two components: an acetabular shell and a liner. it is supplied sterile. the orthocentric cross linked polyethylene liner is intended for use in total hip arthroplasty. total hip arthroplasty (tha) is indicated for a hip joint replacement in order to provide increased patient mobility and reduce pain where there is evidence of sufficient sound bone to seat and support the components. treatment selection for their patient is the surgeon?s responsibility. when a surgeon has selected total hip arthroplasty as the preferred treatment, the devices are indicated for: - osteoarthritis or post traumatic osteoarthritis - rheumatoid arthritis. - correction of functional deformity. - avascular necrosis of the femoral head or neck. - acute traumatic fracture of the femoral head or neck. - revision of any unsuccessful previous hip surgery or where other treatments or devices have failed. - certain cases of ankylosis. - hip dysplasia (painful or congenital) - severely painful and/or disabled joint the acetabular components are intended for cementless fixation.

SYNVISC DISPO INTRA-ARTICULAR INJECTION 2mL (サイビスクディスポ関節注2mL) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

synvisc dispo intra-articular injection 2ml (サイビスクディスポ関節注2ml)

sanofi k.k. - sodium hyaluronate crosslinked polymer; sodium hyaluronate crosslinked polymer crosslinked with vinylsulfone - injection

MyCareLink™ Patient Monitor and Reader Singapore - English - HSA (Health Sciences Authority)

mycarelink™ patient monitor and reader

medtronic international, ltd. - cardiovascular - the monitor is an external electronic device that interfaces with medtronic implanted heart devices and a telecommunications connection to transmit stored implanted heart device data to the physician or clinician. the medtronic model 24955 reader is intended for use only with medtronic mycarelink model 24950 or medtronic mycarelink model 24951 patient monitors.

PHOTREXA VISCOUS- riboflavin 5-phosphate in 20% dextran ophthalmic solution/ drops
PHOTREXA- riboflavin 5-phosphate ophthalmic solution/ drops
PHOTREXA CROSS-LINKING KIT- riboflavin 5-phosphate ophthalmic kit United States - English - NLM (National Library of Medicine)

photrexa viscous- riboflavin 5-phosphate in 20% dextran ophthalmic solution/ drops photrexa- riboflavin 5-phosphate ophthalmic solution/ drops photrexa cross-linking kit- riboflavin 5-phosphate ophthalmic kit

glaukos corporation - riboflavin 5'-phosphate sodium anhydrous (unii: 957e53wv42) (riboflavin 5'-phosphate - unii:7n464ure7e) - flavin mononucleotide 1.46 mg in 1 ml - photrexa® viscous and photrexa® are indicated for use in corneal collagen cross-linking in combination with the kxl™ system for the treatment of none. risk summary animal development and reproduction studies have not been conducted with the photrexa® viscous/photrexa® /kxl® system. since it is not known whether the corneal collagen cross-linking procedure can cause fetal harm or affect reproduction capacity, it should not be performed on pregnant women. risk summary there are no data on the presence of photrexa viscous or photrexa in human milk, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for the photrexa/kxl corneal collagen cross-linking procedure and any potential adverse effects on the breastfed child from the photrexa/kxl corneal collagen cross-linking procedure or from the underlying maternal condition. the safety and effectiveness of corneal collagen cross-linking has not been established in pediatric patients below the age of 14 years. no patients enrolled in the clinical studies were 65 years of age or older.

Dapsone (Link) New Zealand - English - Medsafe (Medicines Safety Authority)

dapsone (link)

link pharmaceuticals ltd - dapsone 100mg - tablet - 100 mg - active: dapsone 100mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose - dermatitis herpetiformis.

Dapsone (Link) New Zealand - English - Medsafe (Medicines Safety Authority)

dapsone (link)

link pharmaceuticals ltd - dapsone 25mg - tablet - 25 mg - active: dapsone 25mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose - dermatitis herpetiformis.

Hangzhou Singclean SingFiller Cross-Linked Sodium Hyaluronate Gel for Plastic Surgery Singapore - English - HSA (Health Sciences Authority)

hangzhou singclean singfiller cross-linked sodium hyaluronate gel for plastic surgery

sindor healthcare pte. ltd. - general & plastic surgery - singfiller is intended to be used for facial tissue augmentation. it is recommended to be used for the correction of wrinkles and for lip enhancement after accidents and trauma.

Filorga X-HA Volumne Cross-linked Hyaluronic Acid Filler Singapore - English - HSA (Health Sciences Authority)

filorga x-ha volumne cross-linked hyaluronic acid filler

laponie (s) pte ltd - general & plastic surgery - x-ha® volume ha filler is an injectable biodegradable cross-linked hyaluronic acid gel to increase or restore volume of the face, remodel facial contours and correct deeper wrinkles and folds; it is indicated for injection into the deep dermis, subcutis or supraperiosteally.

Hipraviar TRT Formulation:   Each 0.5 mL (dose) contains:   Turkey Rhinotracheitis Virus (1062 Strain) .......... >196 Titre expressed in ELISA Units ELISA - Enzyme-Linked Immunosorbent Assay Emulsion for Injection (IM/SC) Philippines - English - FDA (Food And Drug Administration)

hipraviar trt formulation: each 0.5 ml (dose) contains: turkey rhinotracheitis virus (1062 strain) .......... >196 titre expressed in elisa units elisa - enzyme-linked immunosorbent assay emulsion for injection (im/sc)

hipra philippines, inc.; distributor: hipra philippines, inc. - inactivated turkey rhinotracheitis virus vaccine (vet.) - emulsion for injection (im/sc) - formulation: each 0.5 ml (dose) contains: turkey rhinotracheitis virus (1062 strain) .......... >196 titre expressed in elisa units elisa - enzyme-linked immunosorbent assay